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ABSTRACT 
We examined the dose of radiation received during diagnosis of lung cancer as 
this may add to the risk of a second primary cancer.  Patients undergoing surgery 
(n=40) or (chemo)radiotherapy (n=40) received comparable doses (28.6 mSv 
and 25.8mSv respectively), significantly higher than for supportive care (n=40; 
15.1mSv).  The effective dose of radiation received was higher for early stage 
disease than for those with metastatic disease.  The mean lifetime attributable 
risk of malignancy for those receiving treatment with curative intent in our 
cohort was 0.059% and lung specific risk 0.019%. 
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INTRODUCTION 
During work-up of patients with (suspected) lung cancer for treatment with 
curative intent, healthy tissues are exposed to ionising radiation.  This may add 
to the risk of a future second primary cancer and is particularly pertinent to the 
growing number of younger long-term survivors.  At present the total radiation 
dose received by patients during diagnostic work-up is not monitored or 
restricted and there remains a paucity of literature on the subject.  
 
Given recent changes in investigation algorithms used in lung cancer [1] and the 
importance of understanding the risks associated with ionising radiation, we 
sought to evaluate diagnostic radiation exposure in a cohort of patients 
investigated through the Papworth and Addenbrookes Thoracic Oncology 
Service. 
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METHODS 
The cumulative radiation dose received by patients undergoing investigation for 
treatment with curative intent for primary lung cancer at Papworth and 
Addenbrooke’s Hospitals between December 2012 and March 2014 was 
calculated.  Retrospective data were gathered from electronic reporting systems 
including patient demographics, stage and type of cancer and participation in 
clinical studies involving ionising radiation (supplementary Tables 1-4 online 
data).  Information on all radiological investigations involving ionizing radiation 
between the first targeted investigation and the start of definitive treatment was 
gathered.  Similar data for a group of patients (n=40) undergoing best supportive 
care (BSC) were also collected.  If data on individual studies were not available, 
an estimate derived from local diagnostic reference levels was used. The total 
effective radiation dose was calculated for each patient and percentage lifetime 
attributable risk (LAR) estimated using conversion co-efficients in HPA-CRCE-
028 and -012, NRPB-W67 and ICRP106 [2, 3, 4, 5].   
 
Comparisons between groups were made using Student’s t-test with a P value of 
<0.05 considered significant.  
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RESULTS 
The mean cumulative dose of radiation received by 80 patients undergoing 
investigation for treatment with curative intent (surgery or radical 
(chemo)radiotherapy) was 27.6 mSv ± 0.9 (Table 1).  Patients in the surgical and 
(chemo)radiotherapy groups received comparable doses - surgery 28.6 mSv, 
CRT 25.8 mSv; p=0.89 (Table 1 and Figure 1).  This was significantly higher than 
those who received BSC (n=40; 15.1 mSv ± 1.4; p<0.05).  When stratified by the 
stage of disease (Figure 2), the effective dose of radiation received was higher for 
early stage disease than for those with metastatic disease (μ = 26.9 mSv for stage 
I, 24.6 mSv for stage II, 22.3 mSv for stage III and 14.4 mSv for stage IV).  As 
might be expected there was a correlation between body mass and effective dose 
(Supplementary Figure 1; r=0.44, p<0.05) but no significant correlation with 
patient age (Supplementary Figure 2; r=0.058, p=0.52).  For patients undergoing 
treatment with curative intent the median number (range) of investigations 
undertaken was CT staging 1 (0-4); CT head 1 (0-2); CT guided biopsy 1 (0-3) 
and PET-CT 1 (0-2) (supplementary Table 5 on-line data).   
 
 
The mean lifetime attributable risk (LAR) of malignancy for those receiving 
treatment with curative intent was 0.059% i.e. 5.9 in 10,000 long-term survivors 
would be expected to develop a second primary cancer as a direct consequence 
of diagnostic imaging investigations.  The lung specific risk was 0.019% (Table 
2).  
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DISCUSSION 
Despite lung cancer being one of the most common cancers globally there is a 
paucity of information on the usual radiation dose patients receive during 
diagnostic work-up.  We have shown that the mean cumulative dose of radiation 
received by patients undergoing investigation for treatment with curative intent 
(surgery, radical (chemo)radiotherapy) is around 28 mSv substantially lower 
than that identified by Stiles et al (2011) who found that in 94 patients, the 
three-year median estimated dose was 84.0 mSv and that the highest dose 
occurred in the pre-operative year [6].  In any one year 66% of their patients 
received more than 50 mSV while 19% received over 100 mSv.  Only one of our 
80 patients exceeded 50 mSv.  Our finding that the radiation dose received by 
those who ultimately received treatment with curative intent was significantly 
higher than the dose received for those treated with BSC is not unexpected.  This 
is because those being assessed for treatment with curative intent underwent 
additional investigations including PET-CT and CT head and some patients being 
assessed for surgical resection required coronary angiography and/or 
quantitative ventilation/perfusion scintigraphy.  The overall reduction in 
radiation dose compared to the work by Stiles et al (2011) is most likely due to 
improvements in radiation technology over the last decade, which allows 
equivalent imaging at lower radiation doses [6].   
 
Although we have estimated the associated LAR of malignancy this value 
remains difficult to interpret with regards to setting ‘limits’ of acceptability.  
Typically, LAR values are calculated in healthy subjects but the effect of radiation 
exposure in a high-risk tobacco exposed population may be greater.  A number of 
factors should be considered.  Age at presentation may be significant.  For 
patients presenting over age 70 the risk of developing a second primary cancer 
as a result of previous radiation exposure is likely to be considerably lower than 
the risk conferred by previous/current cigarette smoking.  However for younger 
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patients being treated with curative intent, thought should be given to LAR given 
that they will likely have longer life expectancy.   
 
In conclusion, newer algorithms for investigating patients with suspected lung 
cancer, combined with improvements in imaging technology have reduced the 
average radiation dose in patients receiving definitive treatment to 28 mSv.  
Although this is considerably lower than previous reports it is still associated 
with a quantifiable mean LAR of malignancy of 0.059% in our patient cohort.   
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TABLES 
 
Table 1 Effective dose of radiation received/mSv 
Treatment Group N 
Mean/µ (95% 
CI) 
SEM SD/σ 
Surgical 40 28.6 (26.0-31.2) 1.33 8.42 
(Chemo)radiotherapy 40 25.8 (23.5-28.1) 1.19 7.50 
Total curative intent 80 27.6 (25.8-29.4) 0.90 8.01 
Best supportive care 40 15.1 (12.4-17.8) 1.36 8.60 
 
 
 
 
 
 
 
 
Table 2 Lifetime added risk of malignancy/% 
Treatment Group N 
Total Lung 
Mean/µ SEM SD/σ Mean/µ SEM SD/σ 
Surgical 40 0.062 0.00013 0.00082 0.019 0.00011 0.00072 
(Chemo)radiotherapy 40 0.056 0.00015 0.00097 0.019 0.00026 0.00017 
Total curative intent 80 0.059 0.00014 0.00090 0.019 0.000019 0.00012 
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FIGURE LEGENDS 
 
Figure 1 
Effective radiation dose (mSv) received by patients during diagnostic work-up 
stratified by surgical, (chemo)radiotherapy (CRT) and best supportive care 
(BSC) groups.  
 
 
Figure 2 
Effective radiation dose (mSv) received by patients during diagnostic work-up 
stratified by stage of disease. 
 
 
 
Supplementary Figures 
 
Figure 1 
Effective radiation dose (mSv) as a function of weight (kg) for all patients 
(n=120). 
 
Figure 2 
Effective radiation dose (mSv) as a function of age (yrs) stratified by stage of 
disease (I-IV). 
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Main Figure 1 
 
 
 
Main Figure 2 
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Supplementary Figure 1 
 
 
 
Supplementary Figure 2 
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Supplementary Table 1 Patient demographics 
 
Supplementary Table 2 Stage of malignancy 
  
Treatment Group 
Sex/n Median age/years 
Male Female  
Surgical 24 16 71.5 
Chemoradiotherapy 24 16 73 
Total curative intent 48 32 72 
Best supportive 
care 
18 22 71 
Total 66 54 72 
Treatment Group 
Stage 
1a 1b 2a 2b 3a 3b 4 
Surgical 17 13 3 3 4 0 0 
Chemoradiotherapy 10 8 3 2 14 3 0 
Total curative intent 27 21 6 5 18 3 0 
Best supportive 
care 
0 5 1 2 5 5 22 
Total 27 26 7 7 22 8 22 
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Supplementary Table 3 Histological type of lung cancer 
 
Supplementary Table 4 Clinical Trials 
 
  
Treatment Group 
Type 
NSCLC SCLC Mixed Unknown 
Surgical 39 0 1 0 
Chemoradiotherapy 36 0 0 4 
Total curative intent 75 0 1 4 
Best supportive 
care 
34 5 0 1 
Total 109 5 1 5 
Treatment Group 
SPUTNIK TIDAL 
Lung-
SEARCH 
UKLS None 
Surgical 2 1 1 1 35 
Chemoradiotherapy 2 0 0 1 37 
Total curative intent 4 1 1 2 72 
Best supportive 
care 
2 0 0 0 38 
Total 6 1 1 2 110 
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Supplementary Table 5 Median (range) number of investigations involving ionizing radiation performed for each treatment group.  
 
 
Treatment Group 
CXR CT Staging CT Head 
CT-guided 
biopsy 
CTPA PET-CT 
Coronary 
angiogram 
V/Q scan 
Median 
(Range) 
Mean/ 
µ 
Median 
(Range) 
Mean/ 
µ 
Median 
(Range) 
Mean/ 
µ 
Median 
(Range) 
Mean/ 
µ 
Median 
(Range) 
Mean/ 
µ 
Median 
(Range) 
Mean/ 
µ 
Median 
(Range) 
Mean/ 
µ 
Median 
(Range) 
Mean/ 
µ 
Surgical 3 (1-7) 2.90 1 (0-4) 1.55 1 (0-2) 1.00 1 (0-2) 0.83 0 (0-1) 0.05 1 (0-1) 1.00 0 (0-1) 0.05 0 (0-1) 0.05 
(Chemo)radiotherapy 2 (0-8) 2.33 1 (0-3) 1.45 1 (0-2) 1.00 0 (0-3) 0.54 0 (0-1) 0.05 1 (0-2) 1.05 0 (0-0) 0.00 0 (0-1) 0.13 
Total curative intent 2 0-8) 2.62 1 (0-4) 1.50 1 (0-2) 1.00 1 (0-3) 0.68 0 (0-1) 0.05 1 (0-2) 1.03 0 (0-1) 0.03 0 (0-1) 0.09 
Best supportive care 1 (0-8) 1.60 1 (0-3) 1.23 0 (0-1) 0.23 0 (0-2) 0.20 0 (0-1) 0.10 0 (0-1) 0.48 0 (0-0) 0.00 0 (0-1) 0.03 
